Global Cell and Gene Therapy Market Share, Size, Drivers, Opportunitues: By Type: Cell Therapy Types, Gene Therapy Types; By Indications: Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases, Dermatology, Endocrine, Metabolic, Genetic, Others; By Product Type; By End User; Regional Analysis; Supplier Landscape; 2023-2031

Global Cell and Gene Therapy Market Outlook

The global cell and gene therapy market size attained a value of USD 17.4 billion in 2022. The market is expected to rise at a CAGR of 23.17% during the forecast period of 2023-2031 to attain a value of USD 113.64 billion by 2031, driven by the rising prevalence of chronic diseases.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cell and Gene Therapy: A Brighter Future Outlook

The global cell and gene therapy market is a comparatively new integration of technology and genomics, that has been enthralled by substantial new developments in the healthcare industry. Cell and gene therapy are the two conjoining therapies incorporated as a single therapy for efficient and effective treatment. The emerging new cell and gene therapies are sure to burgeon the biotechnological and biopharmaceutical industry in the coming years.

Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In cell therapy, cells are modified outside the body, that is, in ex-vivo conditions and then injected into the patient. On the other hand, gene therapy works by incorporating, deactivating, or displacing the genes into cells which can occur both inside (in vivo) and outside (ex vivo) of the body.

In the healthcare sector, some of the major treatments and curative remedies are developed using cell and gene modifications. Cell and gene therapy works by modifying the genes in particular cells and injecting them into the body. The essential resemblance between cell and gene therapy is the ability to mitigate the underlying cause of genetic disorders. There are enormous cell and gene therapies based on the origin or destination as per the treatment requirements.

Based on the genetic manipulation and source, cell and gene therapies are classified into two categories- ex vivo and in vivo. The ex vivo ones are further categorised into allogenic and autologous.

Autologous therapies require raw materials to be referenced and returned to the same subject. At the same time, allogeneic therapies deliver it through material from any optimum donor. Cell therapies utilise genetically modified (for example CAR-T therapy) and non-genetically modified cells (Beta cells T1D) as medicines. In contrast, gene therapies use viral (lipid/polymer based) and non-viral (mRNA) vectors as medicines.

Researchers are working on several new cell and gene therapies in the new disease sectors, which will help in improving the overall market outlook.

Market Segmentations

According to the cell and gene therapy market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

• Cell Therapy Types
  • Autologous Cell Therapy
  • Autogenic Cell Therapy
  • Ex-vivo Cell Therapy
  • In-vivo Cell Therapy
• Gene Therapy Types
  • Somatic Cell Gene Therapy
  • Germline Gene Therapy
  • Ex-vivo Gene Therapy
  • In-vivo Gene Therapy

Market Breakup by Indications

• Oncology

• Cardiology

• CNS

• Musculoskeletal

• Infectious Diseases

• Dermatology

• Endocrine, Metabolic, Genetic

• Immunology and Inflammation

• Ophthalmology

• Haematology

• Gastroenterology

• Others

Market Breakup by Product Type

• Yescarta

• Provenge

• Luxtura

• Kymriah

• Imlygic

• Gintuit

• MACI

• Laviv

• Gendicine

• Oncorine

• Neovasculgen

• Strimvelis

• Invossa

• Zolgenesma

• Tecartus

• Lisocel

• Zyntelego

• Others

Cell and Gene Therapy Market Breakup by End User

• Hospitals

• Ambulatory Surgical Centres

• Wound Care Centres

• Cancer Care Centres

• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cell and Gene Therapy Market Scenario

The emerging cell and gene therapies seem promising in commercial aspects. Key market leaders will be the gene therapy companies that will provide fast and effective treatment for debilitating diseases. Gene therapies developed by small, medium, and big biotech and pharmaceutical companies also tend to attract the attention of investors. According to Food and Drug Administration’s anticipation, by 2025, 10 to 20 new cell and gene therapies can be approved.

According to the research surveys, publicly traded cell and gene therapies also witnessed a 70% increase in stocks compared to the previous year. This demonstrates the substantial growth of the cell and gene therapy market in the upcoming years.

The increase in the prevalence of chronic disorders, like cancer, is responsible for driving the growth of this market. The increased expenditure in the R&D sector and enhanced government support are also expected to boost the cell and gene therapy market development during the forecast period.

Advanced technologies and better healthcare infrastructure facilities are the additional factors helping in the development of this market.

Based on regions, North America accounts for a significant share of the global market due to the growth of the market in the United States. The United States of America has witnessed a substantial increase in biopharmaceutical companies performing clinical trials in cell and gene therapy. Thus, the United States hold a significant share in the global cell and gene therapy market.

The growth of the market in the United States can be attributed to the higher presence of the key players in the region. It was found that more than 1000 companies worldwide are working on cell and gene therapy, out of which more than 500 companies are based in the United States.

Across the globe, around 250 are from Europe, about 150 are in the Asian region and the rest are found in other regions like Oceania, New Zealand, Australia, and Africa.

Therapeutic Landscape

Over the last decade, cell and gene therapy have accelerated and resulted in multiple effective treatments for various indications. These novel therapies and strategies have grabbed the attention of the entire biotech and pharma industry and are visible as future hallmarks of the global cell and gene therapy market. The field of cell and gene therapy is still young compared to other modalities.

A collaborative industry effort has focused on applying chimeric anti-receptor T-cells for oncology indications. The incorporation of cell and gene therapy in hematopoietic stem cells has paved the pathway for new therapeutic strategies, including haematological, neurological, and ocular symptoms.

Emerging Regenerative Medicine and Gene Alteration Technologies

Novartis Pharmaceuticals were doing clinical trials to monitor the long-term safety of CAR-T patients. The purpose of this trial was to monitor all patients who were incorporated with CAR-T therapies for fifteen years following their last CAR-T infusion.

Researchers did clinical trials for the first FDA-approved in vivo therapy to treat retinal dystrophies caused by the modified RPE65 gene. This therapy is incorporated with the help of the adeno-associated vector, which will target the retinal cells and insert the healthy genes into the patient’s eye.

Cell and gene therapy for Haemophilia is also entering the last stage of the clinical trials. There are already ten ongoing trials for Haemophilia A and six for Haemophilia B. In this therapy, a single injection of adeno-associated virus (AAV) is engineered in the liver to produce the essential clotting factor for the rest of the patient’s life.

Another set of clinical trials utilising cell and gene alteration is under process in the United States to treat degenerative retinal diseases. In this therapy, an intraocular injection pass on the genes encoding for MCO protein into the retinal cells. These trials are also in the phase II stage.

Implementing cell and gene technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for cell and gene therapies. A rapid rise in authorisations for gene therapies is also expected. Careful planning and research are done to overcome all the hurdles and hindrances and for the vast development.

Several ongoing clinical trials are emerging as a driving factor for cell and gene therapy market growth and development.

Competitive Landscape

The report gives an in-depth therapy and the key players involved in the cell and gene therapy market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Amgen, Inc.

• Bluebird Bio, Inc.

• Castle Creek Pharmaceutical Holdings

• Kite Pharma, Inc.

• Novartis AG

• Orchard Therapeutics plc.

• Pfizer, Inc.

• Spark Therapeutics, Inc.

• Vericel Corporation

• Vericel Corporation

• Human Stem Cells Institute

• Kolon Tissuegene Inc.

• Organogenesis Holdings Inc.

Key Highlights of the Report

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.